Danilo R Casimiro

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. pmc Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene
    Danilo R Casimiro
    Department of Virus and Cell Biology, Merck Research Laboratories, Merck and Company, West Point, Pennsylvania 19486, USA
    J Virol 76:185-94. 2002
  2. pmc Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene
    Danilo R Casimiro
    Department of Viral Vaccine Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    J Virol 77:7663-8. 2003
  3. pmc Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag
    Danilo R Casimiro
    Department of Vaccines and Biologics Research, Merck Research Laboratories, Merck and Co, West Point, Pennsylvania 19486, USA
    J Virol 79:15547-55. 2005
  4. doi request reprint Design and optimization of a multiplex anti-influenza peptide immunoassay
    James E Drummond
    Merck Research Laboratories, West Point, PA 19486, USA
    J Immunol Methods 334:11-20. 2008
  5. pmc Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors
    Danilo R Casimiro
    Department of Viral Vaccine Research, Merck Research Laboratories, Merck and Co, 770 Sumneytown Pike, West Point, PA 19486, USA
    J Virol 78:11434-8. 2004
  6. pmc Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene
    Danilo R Casimiro
    Department of Viral Vaccine Research, Merck and Company, West Point, Pennsylvania 19486, USA
    J Virol 77:6305-13. 2003
  7. pmc Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge
    Danilo R Casimiro
    Department of Vaccines Basic Research, Merck Research Laboratories, Merck and Co, West Point, Pennsylvania 19486, USA
    J Virol 84:2996-3003. 2010
  8. pmc Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys
    Xiaoping Liang
    Merck Research Laboratories, P O Box 4, WP16 306, West Point, PA 19486, USA
    J Virol 79:12321-31. 2005
  9. ncbi request reprint Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
    John W Shiver
    Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    Nature 415:331-5. 2002
  10. ncbi request reprint The impact of early immune destruction on the kinetics of postacute viral replication in rhesus monkey infected with the simian-human immunodeficiency virus 89.6P
    Zhi qiang Zhang
    Department of Viral Vaccine Research, Merck Research Laboratories, West Point, PA 19486, USA
    Virology 320:75-84. 2004

Detail Information

Publications36

  1. pmc Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene
    Danilo R Casimiro
    Department of Virus and Cell Biology, Merck Research Laboratories, Merck and Company, West Point, Pennsylvania 19486, USA
    J Virol 76:185-94. 2002
    ..Thus, optimizing the immunogenic properties of HIV-1 Pol at the level of the gene sequence validates it as an antigen and provides an important step toward the construction of a potent pol-based HIV-1 vaccine component...
  2. pmc Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene
    Danilo R Casimiro
    Department of Viral Vaccine Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    J Virol 77:7663-8. 2003
    ..The implications of these results are discussed...
  3. pmc Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag
    Danilo R Casimiro
    Department of Vaccines and Biologics Research, Merck Research Laboratories, Merck and Co, West Point, Pennsylvania 19486, USA
    J Virol 79:15547-55. 2005
    ..However, virus control was short-lived, and indications of viral escape were evident as early as 6 months postinfection. The implications of these results in vaccine design and clinical testing are discussed...
  4. doi request reprint Design and optimization of a multiplex anti-influenza peptide immunoassay
    James E Drummond
    Merck Research Laboratories, West Point, PA 19486, USA
    J Immunol Methods 334:11-20. 2008
    ..Assay reagents and parameters have been optimized and the assay is shown to be repeatable and robust. The assay will be used to support clinical vaccine trials of a bivalent peptide vaccine...
  5. pmc Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors
    Danilo R Casimiro
    Department of Viral Vaccine Research, Merck Research Laboratories, Merck and Co, 770 Sumneytown Pike, West Point, PA 19486, USA
    J Virol 78:11434-8. 2004
    ..The heterologous Ad5 priming-poxvirus boosting approach may have potential utility in humans as a means of inducing high levels of cellular immunity...
  6. pmc Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene
    Danilo R Casimiro
    Department of Viral Vaccine Research, Merck and Company, West Point, Pennsylvania 19486, USA
    J Virol 77:6305-13. 2003
    ....
  7. pmc Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge
    Danilo R Casimiro
    Department of Vaccines Basic Research, Merck Research Laboratories, Merck and Co, West Point, Pennsylvania 19486, USA
    J Virol 84:2996-3003. 2010
    ..The implications of these results in light of the recent discouraging results of the phase IIb study of the trivalent Ad5 HIV-1 vaccine are discussed...
  8. pmc Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys
    Xiaoping Liang
    Merck Research Laboratories, P O Box 4, WP16 306, West Point, PA 19486, USA
    J Virol 79:12321-31. 2005
    ..The implications of these results in the development of an HIV-1 vaccine will be discussed...
  9. ncbi request reprint Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
    John W Shiver
    Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    Nature 415:331-5. 2002
    ..The replication-defective adenovirus is a promising vaccine vector for development of an HIV-1 vaccine...
  10. ncbi request reprint The impact of early immune destruction on the kinetics of postacute viral replication in rhesus monkey infected with the simian-human immunodeficiency virus 89.6P
    Zhi qiang Zhang
    Department of Viral Vaccine Research, Merck Research Laboratories, West Point, PA 19486, USA
    Virology 320:75-84. 2004
    ....
  11. ncbi request reprint Early depletion of proliferating B cells of germinal center in rapidly progressive simian immunodeficiency virus infection
    Zhi qiang Zhang
    Department of Vaccines and Biologics Research, Merck Research Laboratories, West Point, PA 19486, USA
    Virology 361:455-64. 2007
    ....
  12. doi request reprint Enhanced in vivo transgene expression and immunogenicity from plasmid vectors following electrostimulation in rodents and primates
    Adam J Simon
    Department of Alzheimer s Research, Merck Research Laboratories, West Point, PA 19486, USA
    Vaccine 26:5202-9. 2008
    ..Compared to an efficient viral Ad5 vector system, the gene expression levels of DNA+electrostimulation were surprisingly within a factor of four of the viral delivery system...
  13. ncbi request reprint Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay
    Sheri Dubey
    Department of Vaccine and Biologics Research, Merck Research Laboratories, West Point, PA 19486, USA
    J Acquir Immune Defic Syndr 45:20-7. 2007
    ....
  14. ncbi request reprint Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC
    Lisa S Kierstead
    Vaccine and Biologics Research, Merck Research Laboratories, West Point and Wayne, PA 19087, USA
    AIDS Res Hum Retroviruses 23:86-92. 2007
    ..These studies establish the importance of optimal conditions for PBMC collection and handling to the success of a clinical development program...
  15. pmc Mamu-A*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection
    Zhi qiang Zhang
    Department of Viral Vaccine Research, Merck Research Laboratories, 770 Sumneytown Pike, PO Box 4, WP16 225, West Point, PA 19486, USA
    J Virol 76:12845-54. 2002
    ..These data indicate that MHC class I allele-restricted CTL responses may play an important role in preservation of lymphoid tissue structure, thereby resulting in attenuation of disease progression in immunodeficiency virus infection...
  16. pmc Sustained peptide-specific gamma interferon T-cell response in rhesus macaques immunized with human immunodeficiency virus gag DNA vaccines
    Michael J Caulfield
    Department of Virus and Cell Biology, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    J Virol 76:10038-43. 2002
    ..7 epitopes. The results indicate that a broad and durable CMI response to HIV DNA vaccines can be induced in a relevant nonhuman primate model...
  17. ncbi request reprint PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination
    Adam C Finnefrock
    Vaccine Basic Research, Merck Research Laboratories, West Point, PA 19486, USA
    J Immunol 182:980-7. 2009
    ..05) increase in the peak percentage of T cells specific for the CM9 Gag epitope. These new results on PD-1 blockade in nonhuman primates point to a broader role for PD-1 immunomodulation and to potential applications in humans...
  18. ncbi request reprint Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques
    Daria J Hazuda
    Department of Biological Chemistry, Merck Research Laboratories, Post Office Box 4, West Point, PA 19486, USA
    Science 305:528-32. 2004
    ..These studies demonstrate integrase inhibitor activity in vivo and suggest that cellular immunity facilitates chemotherapeutic efficacy in retroviral infections...
  19. doi request reprint Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans
    Andrew J Bett
    Department of Vaccine Basic Research, Merck Research Laboratories, West Point, PA 19486 0004, USA
    Vaccine 28:7881-9. 2010
    ....
  20. doi request reprint Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus
    Tong Ming Fu
    Department of Vaccines Research, Merck Research Laboratories, West Point, PA, United States
    Vaccine 30:7469-74. 2012
    ....
  21. pmc DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles
    Kara S Cox
    Department of Vaccine Basic Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    J Virol 82:8161-71. 2008
    ..Implications of these results for future vaccine development will be discussed...
  22. ncbi request reprint A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV Type 1 gag vaccinated human subjects
    Timothy W Tobery
    Department of Vaccines and Biologics Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    AIDS Res Hum Retroviruses 22:1081-90. 2006
    ....
  23. doi request reprint Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus
    Tong Ming Fu
    Department of Vaccine Basic Research, West Point, PA 19002, USA
    Virology 385:218-26. 2009
    ..The implications of these results in antiviral mechanisms of immune responses induced by M2 vaccines are discussed...
  24. ncbi request reprint Development of stable liquid formulations for adenovirus-based vaccines
    Robert K Evans
    Department of Vaccine Pharmaceutical Research, Merck Research Laboratories, WP78 302, Sumneytown Pike, West Point, PA 19486, USA
    J Pharm Sci 93:2458-75. 2004
    ..The identification of 4 degrees C stable liquid formulations should significantly enhance the utility of Ad5 as a vector for vaccines and gene therapy...
  25. ncbi request reprint HIV type 1 vaccines for worldwide use: predicting in-clade and cross-clade breadth of immune responses
    Adam C Finnefrock
    Vaccine and Biologics Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    AIDS Res Hum Retroviruses 23:1283-92. 2007
    ..For more diverse proteins, adding a second strain can add a significant increase in breadth, although for three or more strains the intrinsic diversity of the protein leads to diminishing improvement...
  26. ncbi request reprint Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines
    Miguel Aste-Amezaga
    Department of Virus and Cell Biology, Merck Research Laboratories, Merck and Co, Inc, West Point, PA 19486, USA
    Hum Gene Ther 15:293-304. 2004
    ..The evaluation of serotype-specific neutralizing antibodies can be of both clinical and epidemiologic importance as a means of selecting the appropriate serotype adenovector(s)...
  27. doi request reprint Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection
    Dai Wang
    Department of Vaccine Research, Merck Research Laboratories, WP16 200, 770 Sumneytown Pike, West Point, PA 19486, United States
    Vaccine 29:9075-80. 2011
    ..The serum neutralizing activities were maintained at high levels throughout the child bearing age. The corresponding titers may serve as a biomarker for CMV vaccine efficacy...
  28. doi request reprint A novel high-throughput neutralization assay for supporting clinical evaluations of human cytomegalovirus vaccines
    Aimin Tang
    Vaccines Research, Merck Research Laboratories, West Point, PA, USA
    Vaccine 29:8350-6. 2011
    ..Lastly, to demonstrate the utility of this assay to support HCMV vaccine study, we presented the results of neutralizing titers from a rhesus macaque vaccination study...
  29. doi request reprint International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials
    T Christopher Mast
    Merck Research Laboratories, West Point, PA, USA christopher
    Vaccine 28:950-7. 2010
    ..Coincident Ad5/6 titers were lower than either Ad5 or Ad6 titers alone. Understanding pre-existing immunity to candidate vaccine vectors may contribute to the evaluation of vaccines in international populations...
  30. ncbi request reprint Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroon
    Swati B Gupta
    Merck and Co, Inc, Whitehouse Station, NJ, USA
    J Acquir Immune Defic Syndr 42:135-9. 2006
    ..Substantial cross-clade cell-mediated immune responses in Botswana and Cameroon confirm previous findings in a larger, more genetically diverse collection of HIV-1 samples...
  31. ncbi request reprint Characterization and biological evaluation of a microparticle adjuvant formulation for plasmid DNA vaccines
    Robert K Evans
    Department of Vaccine Pharmaceutical Research, Merck Research Laboratories, WP78 302, Sumneytown Pike, West Point, Pennsylvania 19486, USA
    J Pharm Sci 93:1924-39. 2004
    ..These results indicate that the addition of BAK to DNA/CRL1005 formulations leads to the formation of approximately 300 nm CRL1005-BAK-DNA particles that enhance the cellular immune response in rhesus monkeys...
  32. doi request reprint Evaluating functional antibodies in rhesus monkeys immunized with hepatitis B virus surface antigen vaccine with novel adjuvant formulations
    Daniel C Freed
    Department of Vaccine Basic Research, Department of Vaccine Processing Research and Development, Merck Research Laboratories, West Point, PA, USA
    Vaccine 29:9385-90. 2011
    ....
  33. doi request reprint Role of nonhuman primates in the evaluation of candidate AIDS vaccines: an industry perspective
    Silvija I Staprans
    Merck Vaccines, West Point, Pennsylvania, USA
    Curr Opin HIV AIDS 5:377-85. 2010
    ..To consider how nonhuman primate (NHP) model systems can best contribute to HIV vaccine development...
  34. doi request reprint Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults
    Frances H Priddy
    Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
    Clin Infect Dis 46:1769-81. 2008
    ....
  35. pmc Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaques
    Adrian B McDermott
    Wisconsin National Primate Center, 1220 Capitol Court, Madison, WI 53715, USA
    J Virol 79:15556-66. 2005
    ..These results suggest that viral "breakthrough" in vaccinated animals and viral escape are not inextricably linked and underscore the need for additional research into the mechanisms of vaccine failure...
  36. pmc Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239
    Nancy A Wilson
    Wisconsin National Primate Research Center, University of Wisconsin Madison, Madison, WI 53711, USA
    J Virol 80:5875-85. 2006
    ....